XKRX
200130
Market cap170mUSD
Oct 08, Last price
8,090.00KRW
1D
-0.98%
1Q
-4.15%
Jan 2017
-56.39%
IPO
43.19%
Name
KolmarBNH Co Ltd
Chart & performance
P/E
—
P/S
0.40
EPS
—
Div yield, %
4.73%
Shrs. gr., 5y
-0.08%
Rev. gr., 5y
-1.08%
Revenues
574.88b
-6.62%
Net income
-19.60b
L
CFO
37.90b
-3.30%
Dividend
Aug 28, 202660 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Kolmar BNH Co., Ltd., a South Korean entity, dedicates its efforts to the research and development of cosmetics, health-enhancing functional foods, and advanced functional ingredients, serving both domestic and international markets. Their extensive product portfolio encompasses vitamins and minerals, weight management solutions, sports and nutritional supplements, gut health formulations, and various other offerings tailored for both men and women. Founded in 2004, the company was initially known as Sun Bio Tech before rebranding as Kolmar BNH Co., Ltd. in 2013. Headquartered in Sejong, South Korea, it operates as a subsidiary of Kolmar Korea Holdings Co., Ltd.
Key people
Yeo Won Yoon
Co-Chief Executive Officer, Director · since 2025
Managing Director
Sang Cheol Park
Managing Director
Byeong Sik Gwak
Assistant Managing Director, Chief Security Officer
Jae Yeong Joo
Assistant Managing Director
Gwang Yil Kim
Internal Auditor
Non Executive-Internal Auditor · since 2022
Yeong Jae Shin
Assistant Managing Director
Seung Hwa Lee
Co-Chief Executive Officer, Director · since 2025
Jeong Won Park
Director · since 2022
Co-Chief Executive Officer, Director · since 2025
Hyeon Jun Kim
Other Non-Executive Director
Other Non-Executive Director · since 2025
Chan Lee
Non-Executive Independent Director
Sang Min Oh
Non-Executive Independent Director · since 2025
Jin Su Soh
Non-Executive Independent Director · since 2025
Jeong Bin Yim
Non-Executive Independent Director
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||